Huons Group's 1 Trillion Won Annual Sales Strategy is 'H.O.P.E.'

Leading Management Efficiency through Selection and Focus

Huons Group is accelerating its strategy to enter the 1 trillion KRW sales era.

Huons Group's 1 Trillion Won Annual Sales Strategy is 'H.O.P.E.'

Exterior view of Huons Group's new office building in Pangyo, Seongnam-si, Gyeonggi Province.
[Photo by Huons]

The key to Huons' future growth strategy is ‘H.O.P.E’. This stands for ▲Harmony (maximizing synergy) ▲Overcome (overcoming crises) ▲Pinpoint (selection and concentration) ▲Efficiency (management efficiency).

The holding company Huons Global recorded sales of 664.4 billion KRW and operating profit of 86.4 billion KRW based on consolidated financial statements last year. The sales figure is the largest ever. By business segment, the prescription drug business saw a 40% growth in anesthetic sales due to increased exports of injectables mainly to the North American region. Lidocaine topical anesthetics, which received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA), recorded exports of 12.3 billion KRW to the U.S. and were also approved in Canada.

In the beauty and well-being sector, the female menopause probiotic ‘Eluvi Menolacto’ recorded sales of 38.5 billion KRW as a single brand, continuing its growth trend. The medical device business is also showing strong performance with the growth of the continuous glucose monitor (CGM) ‘Dexcom G6’, diagnostic kit sales, contract manufacturing (CMO), pharmaceutical consignment, and ophthalmic solution consignment.

In the health functional food business, the female menopause probiotic ‘Eluvi Menolacto Probiotics (Menolacto)’ recently achieved cumulative sales of 100 billion KRW as a single product, growing into a mega brand. The company is expanding into the male prostate market with the product ‘Prostate Sagunja’, which contains ‘Sagunja extract powder’.

By affiliate, Huons Foodience is focusing on growing ‘InnerSet’ as a comprehensive health functional food brand while expanding competitiveness in the health functional food OEM (Original Equipment Manufacturer) and ODM (Original Design Manufacturer) markets.

Humedics is concentrating on fillers (Ellavie Premier, Revoline) and botulinum toxin (Liztox). It plans to increase exports to new regions following China, Brazil, and Latin America. Humedics laid the foundation for expanding its CMO business and entering the global market by completing its second factory in 2017. Huons Biopharma is expanding exports to Europe, China, and other regions. Beyond exporting finished products to China, it secured 155.4 billion KRW in capital from IMEIK based on a partnership.

Huons Meditech is focusing on the beauty medical device and quarantine/sterilization markets with its self-developed space sterilizer ‘Huen IVH ER’. In the beauty sector, it promotes the third-generation automatic pressure injection device ‘Derma Shine Pro’. The acne symptom improvement medical device ‘Derma Acne’ is the first comprehensive medical device in Korea combining a pulsed light irradiator, general electrosurgical device, and radiofrequency stimulator.

Over the past decade, Huons Group has completed a business structure linking ‘health functional foods - medical devices - healthcare consumables’ by organically creating synergy among its core businesses?pharmaceuticals (Huons), aesthetics (Humedics)?through mergers and acquisitions (M&A) and open innovation strategies, while discovering new business areas that can serve as growth momentum. It has also signed joint R&D or pipeline introduction contracts with various R&D specialized companies in different fields such as HLB Pharma, Kineta, G2G Bio, One Biogen, and Epibiotech.

A Huons Group official said, "We will discover partners to promote mid- to long-term future growth and contribute to the venture ecosystem in the bio healthcare field. To this end, we will continue to expand strategic investments and new pipelines through open innovation."